New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
09:04 EDTGEVOGevo 30M unit Secondary priced at $.60
Gevo announced that it has agreed to sell 30M common stock units. Each common stock unit consists of one share of common stock and a warrant to purchase 0.5 shares of common stock, at a public offering price of 60c per common stock unit. Each warrant included in a common stock unit will have an exercise price of 85c per share, will be exercisable from the date of original issuance and will expire on August 5, 2019. The shares of common stock and the warrants will be immediately separable and will be issued separately. The gross proceeds to Gevo from this offering are expected to be approximately $18M, not including any future proceeds from the exercise of the warrants. Cowen acted as sole book running manager for the offering.
News For GEVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
18:21 EDTGEVOOn The Fly: After Hours Movers
Subscribe for More Information
16:04 EDTGEVOGevo files to sell common stock and warrants
Gevo announced that it intends to offer and sell, subject to market and other conditions, common stock units. Each common stock unit will consist of one share of common stock, Series A warrants to purchase a certain number of shares of common stock and Series B warrants to purchase a certain number of shares of common stock. The units are to be sold by Gevo subject to market and other conditions in an underwritten public offering. Cowen and Company, LLC is acting as sole manager.
January 27, 2015
09:10 EDTGEVOGevo announces Supreme Court rules in favor of Gevo
Gevo (GEVO) announced that the U.S. Supreme Court ruled in Gevo's favor and overturned an earlier Federal Circuit Court of Appeals ruling on the interpretation of key patent claims. The result is that Gevo's victory in the Delaware District Court is reinstated, and that the case has been remanded back to the Appeals Court for consideration in light of the new standard of appellate review that was decided in the Teva Pharmaceuticals USA, Inc., v. Sandoz, Inc. case last week. In Teva (TEVA), the Supreme Court ruled that the Appeals Court must apply a more stringent "clear error" standard of review, rather than a "de novo" standard of review. In Gevo's case, the Appeals Court must now apply the "clear error" standard of review and cannot set aside the Delaware District Court's findings of fact in Gevo's favor unless they were clearly erroneous. The Supreme Court's decision effectively reinstates Gevo's victory at the District Court where a final judgment of non-infringement was entered in Gevo's favor following the acknowledgment by Butamax Advanced Biofuels LLC that Gevo does not infringe Butamax's Patent Nos. 7,851,188 and 7,993,889.
January 20, 2015
08:46 EDTGEVOGevo announces headcount reduction at headquarters among other measures
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use